NEW YORK — Chronic disease laboratory company Salveo Diagnostics this week announced its acquisition of autoimmune-focused diagnostics firm ImmunArray and health engagement platform Nudge.
Financial and other terms of the deal were not released.
The firms said the merger will expand Salveo's testing abilities and improve communication between providers and patients while also allowing patients to access lab results on their smartphones.
All three companies are based in Richmond, Virginia.
Salveo offers diagnostic testing for a variety of chronic diseases, including heart disease, stroke, and autoimmune disorders.
ImmunArray develops blood-based tests for autoimmune diseases and cancer. Its first product is the SLE-Key Rule-Out Test, which uses iCHIP technology to determine whether a patient has systemic lupus erythematosus or lupus. Next on its slate are additional tests for autoimmune disorders and cancer.
Last October, ImmunArray spun out its traumatic brain injury testing to a new company, BRAINBox Solutions.
Nudge is a mobile health engagement platform allowing providers to remotely offer personalized health coaching and other wellness initiatives.
"We believe that personalized medicine is the only way to reverse the epidemic of chronic disease, and by incorporating the expertise and resources of these two companies, we are even better positioned to support providers and patients alike," Mark Chapman, CEO of Salveo, said in a statement.